Some Wall Street firms are reevaluating policies for drug testing employees. Here’s where the biggest banks stand on testing workers for marijuana use.

Jeremy Berke | Many big banks will be impacted by a new law in New York City that bars employers from forcing job applicants to take drug tests for marijuana use.

Read More »

A private-equity titan who's doubled the money in each of his 7 funds shares the biggest investing lessons he's gathered from 30 years of industry dominance

Joe Ciolli | John Danhakl, a managing partner at Leonard Green & Partners, shares the nine most important lessons he's learned from his 30 years in private equity.

Read More »

Tradeweb just hired a former senior technologist at Citadel for a new role that signals fixed income's increasing focus on trade data

Dan DeFrancesco | Caius Howcroft, who was head of platform technology at Citadel, was named Tradeweb's head of data and platform architecture technologies.

Read More »

A tech exec explains how it feels to spend 1.5 years preparing for a $226 million IPO, only to sell to PayPal for $2.2 billion

Shona Ghosh | iZettle announced its $2.2 billion acquisition by PayPal a day before it was due to publish its IPO documents.

Read More »

Career experts say asking these 8 questions at work will show your CEO that you're a born leader

Shana Lebowitz | Ask these questions during a meeting with your CEO, experts say, so that you look smart, knowledgeable, and engaged.

Read More »

Trump's Huawei ban could hurt chipmakers like Intel and Qualcomm, but one analyst thinks the processor industry has bigger things to worry about

Benjamin Pimentel | Chipmakers are expected to take a hit from the Huawei ban and the broader "tech cold war." But one analyst said the sector faces other problems.

Read More »

New Y Combinator President Geoff Ralston explains why he's so excited about investing in the youngest startups, and his philosophy for helping them to grow

Megan Hernbroth | Geoff Ralston will be taking over as Y Combinator President for Sam Altman, who announced his departure in March.

Read More »

A top exec at GlaxoSmithKline gave us an inside look at the $100 billion pharma giant's experiment with a new way of getting paid for medicines

Emma Court | Drug companies are getting paid based on how well their treatments work. That's more complicated than it sounds.

Read More »

Inside Amazon's battle to put down an unprecedented shareholder revolt over facial recognition

Jake Kanter | Amazon investors are concerned that the Rekognition technology will be used for surveillance and has been found to produce inaccurate results.

Read More »